
MRNA · NASDAQ-GS
Published consensus is inconsistent rather than a single usable figure: one StockAnalysis snippet cites 23 S&P Global analysts at Hold with an $89.33 average, while TipRanks cites 15 analysts, a $40-$170 range and an average implying 52.79% upside; AnaChart reports an $18-$77 range and a $40.08 average. BofA’s Alex Stranahan is the most bullish identifiable actor, moving to Neutral with a $170 target from $40; no named analyst is tied to the $18 low. The supplied record shows no action dated during August 17-21, so revision direction is unknown. The spread reflects different analyst datasets, but no fundamental rationale is supplied.
Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A$427.48
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of$21.77
Regeneron Pharmaceuticals, Inc.$917.65
GSK plc American Depositary Shares (Each representing two Ordinary Shares)$47.70